HER2/neu as a Prognostic Marker and Therapy Target in Prostate Cancers

Vili Pachkoria, Vakhtang Shoshiashvili, Guram Karazanashvili, Gia Burkadze 

Tbilisi State Medical University, Georgia

Prostate cancer is a most common endocrine tumor in men and about every one from six men in northern countries is under the risk of this tumor in old ages. Most common problem in treatment of PC is the development of androgen resistance, the mechanisms of which are not yet completely understood. HER2 may have a role in development of androgen independence, metastasis and prognosis of prostate cancer (PC). HER2 also serves as a molecular target in PC therapy. Different therapeutic strategies are investigated for HER2 targeted therapy in PC. More studies need for the evaluation of diagnostic, prognostic and therapeutic value of HER2 in PC.

Keywords:  prostate cancer, androgen resistance, HER2